ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD-Mediated EMT Signaling Pathway.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The central role of EMT in tumor progression: mechanistic drivers, biomarker discovery, and therapeutic horizons.Frontiers in pharmacology · 2026Review
- ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD-Mediated EMT Signaling Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy marked by high morbidity, recurrence, and metastasis, with limited treatment options and poor prognosis. The challenge of early diagnosis and the inefficacy of current therapeutic strategies underscore the urgent need for novel biomarkers and therapeutic targets. RNA-binding proteins (RBPs) are emerging as critical regulators of post-transcriptional processes and are implicated in cancer progression. Here, the study identifies Staufen Double-Stranded RNA Binding Protein 2 (STAU2) as an oncogenic RBP with high expression in PDAC, which is significantly associated with metastasis. It is demonstrated that STAU2 directly binds and regulates cytoskeletal associated protein Palladin (PALLD) and mediates IQ motif containing GTPase-activating protein 1 (IQGAP1), thereby promoting metastasis via the epithelial-mesenchymal transition (EMT) pathway. Moreover, a 2'-methoxyethoxy (2'-MOE)-modified antisense oligonucleotide (ASO) targeting STAU2 is developed, which effectively inhibited downstream targets in vitro and in vivo. STAU2-ASO treatment significantly suppressed PDAC progression and metastasis, with a demonstrated safety profile in vivo.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.